Gilead Sciences to Present Corporate Update at the UBS Global Life Sciences Conference on Tuesday, September 23, 2003

FOSTER CITY, Calif.--(BUSINESS WIRE)--Sept. 22, 2003--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that it has been invited to present a corporate update to the investment community at the UBS Global Life Sciences Conference in New York on Tuesday, September 23, 2003 at 2:00 p.m. Eastern Time. John Martin, PhD, Gilead's President and Chief Executive Officer, will provide an overview of the company and an update on key business and product development milestones.

To access the live presentation or the seven-day archive via the Internet, log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to view the webcast.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has seven marketed products and focuses its research and clinical programs on anti-infectives. Headquartered in Foster City, CA, Gilead has operations in the United States, Europe and Australia.

For more information on Gilead Sciences, please visit the company's web site at www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).


    CONTACT: Gilead Sciences
             Susan Hubbard, 650-522-5715 (Investor Relations)
             www.gilead.com

    SOURCE: Gilead Sciences, Inc.